Company Overview of Medicago Inc.
Medicago Inc., a clinical-stage biotechnology company, develops novel vaccines and therapeutic proteins to treat various infectious diseases worldwide. The company develops its vaccines based on its proprietary technologies comprising the plant-based Proficia technology and Virus-Like Particles (VLP) technology. Its product candidates include H5N1 pandemic influenza VLP vaccine, which has completed a Phase II human clinical trial; and seasonal influenza and H1N1 vaccines. The company’s products under development also comprise non-influenza VLP and rabies vaccine candidates. It has a strategic alliance with Mitsubishi Tanabe Pharma Corporation to develop a Rotavirus vaccine candidate; and res...
1020 Route de l'Église
Quebec, QC G1V 3V9
Founded in 1997
Key Executives for Medicago Inc.
Chief Executive Officer, President and Director
Executive Vice President of Operations
Director of Investor Relations & Communications
Vice-President of Quality Assurance and Quality Control
Vice President of Manufacturing
Compensation as of Fiscal Year 2014.
Medicago Inc. Key Developments
Medicago Inc. Receives Contract by the U.S. Department of Health and Human Services to Explore Alternate Production Methods for Ebola Antibodies
Feb 24 15
Medicago Inc. announced that it has received a task order from the Biomedical Advanced Research and Development Authority (BARDA) at the U.S. Department of Health and Human Services (HHS) for three anti-Ebola virus monoclonal antibodies (mAbs) with expected performance comparable to that of ZMapp, from Mapp Biopharmaceutical. Medicago will manufacture the antibodies in its Quebec City, Canada facility, for a study in non-human primates (NHP). Two of these antibodies were discovered by the Public Health Agency of Canada. This order is the result of a Task Order Request (TOR) that was solicited by BARDA on December 22, 2014. It is part of the Indefinite Delivery/Indefinite Quantity (ID/IQ) contract between Medicago and the Defense Advanced Research Projects Agency (DARPA).
Medicago Inc. Announces Financial Results for the Second Quarter and Six Months Ended June 30, 2013
Aug 9 13
Medicago Inc. announced financial results for the second quarter and six months ended June 30, 2013. For the quarter, the company reported revenues of $918,000. Net loss was $9,073,000 or $0.04 per basic and diluted share compared to a net loss of $8,099,000 or $0.04 per basic and diluted share for the same period a year ago.
For the six-months, the company reported revenues of $1,337,000. Net loss was $17,789,000 or $0.07 per basic and diluted share compared to $17,087,000 or $0.07 per basic and diluted share for the same period a year ago.
Medicago Inc. to Report Q2, 2013 Results on Aug 09, 2013
Aug 6 13
Medicago Inc. announced that they will report Q2, 2013 results After-Market on Aug 09, 2013
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|